|
|
|
|
|
| First Name: | Leslie | | Last Name: | Shaw | | Title: | Professor | | Advanced Degrees: | PhD | | Affiliation: | University of Pennsylvania Medical Center | | Department: | Pathology and Laboratory Medicine | | Street Address 1: | 3400 Spruce Street | | City: | Philadelphia | | State/Province: | PA | | Zip/Postal Code: | 19104 | Country/Territory: | U.S.A. | | Phone: | 215-662-6575 | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports no financial or other potential conflicts of interest. [Last Modified: 6 July 2005]
|
|
|
View all comments by Leslie Shaw
|
Alzheimer Disease, Parkinson Disease, Aging Process
|
A-beta PP/A-beta, Chemistry/Pharmacology, Clinical trials, Tau/Cytoskeleton, Oxidative Stress
|
Investigations of new small molecule biomarkers of oxidant stress including bioanalytical and clinical validation studies using advanced HPLC/tandem mass spectrometry platforms, using simpler sample preparation techniques and most-sensitive mass spectrometry platforms than heretofore possible.
Investigations involving pharmacokinetics and pharmacodynamics of immunosuppressant drugs in transplant patients and other drug classes. |
49. Shaw LM, Bowers L, Demers L, et al: Critical issues in cyclosporine monitoring: Report of the task force in cyclosporine monitoring. Clin Chem 1987; 33:1269-1288.
74. Mattes RD, Shaw LM, Edling-Owens J, Engelman K: Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behavior 1993; 44:745-747.
153. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. A limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002;48:1497-1504.
153. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. A limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002;48:1497-1504.
160. Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, Shaw LM, Wasik MA. Immunosuppressive signal transduction inhibitor RAD suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft protecting doses. Transplantation, 2003; 75:1710-1717.
76. Kurth CD, Monitto C, Albuquerque ML, Feuer P, Anday E, Shaw LM: Cocaine and its metabolites constrict arterioles in newborn pigs. J Pharmacol Exp Ther 1993; 265:587-591.
80. Roby KAW, Shaw LM: Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J Am Soc Nephrol 1993; 2:168-177.
93. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relationship to pharmacodynamics. Clin Chem 1995, 41:1011-17.
101. Bernard DW, Bowman RL, Grimm FA, Wolf BA, Simson MB, Shaw LM. Nightime dosing assures postdistribution sampling for therapeutic drug monitoring of digoxin. Clin Chem 1996; 42:45-49.
129. Ness R.B., Grisso J.A., Hirschinger M.A., Markovic N., Shaw L.M., Day N.L., Kline J., Cocaine and tobacco use and the risk of spontaneous abortion. New England Journal of Medicine 1999; 340:333-9.
142. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, Silberstein LE, Schuler W, Shaw LM, Wasik MA. Inhibitor of cytokine/growth factor signaling SDZ RAD suppresses growth of human Epstein-Barr virus (EBV)-transformed B lymphocytes in vitro and in vivo; a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders (PTLDs). Proc Natl Acad Sci, 2000;97:4285-90. |
Our ability to diagnose AD at its earliest pre-clinical stage. |
Lee JW, et al, Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005;22:1095-005.
Grossman M, et al, Cerebrospinal fluid profile for tau, Abeta and isoprostanes distinguishes frontotemporal dementia and corticobasal degeneration from Alzheimers Disease. Ann Neurol, in press.
Rokach J, et al, Total synthesis of isoprostanes: discovery and quantitation in biological systems. Chem Physics Lipids 2004;128:35-56.
|
I will give this some thought. |
That AD can be diagnosed earlier than when frankly expressed clinically by use of a combination of biomarker tests (eg, Abeta, Tau, isoprostanes in CSF and possibly other fluids for the latter, imaging data and clinical evaluation. |
Systematic multicenter study in sufficiently large cohorts of patient and control groups, to permit statistically robust evaluation of the clinical utilities of biomarkers for early detection of AD and whether or not the biomarkers track the evolution/progression of the disease. |
|
|
|
|
|
|
Home
